Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Multicenter Extension Trial Evaluating the Efficacy and Safety of UGN-101 (Mitomycin Gel) for Instillation on Ablation of Upper Urinary Tract Urothelial Carcinoma in Recurrent Patients From Trial TC-UT-03

NCT04006691 is registered in ClinicalTrials.gov with UroGen Pharma Ltd. as lead sponsor.

NCT NCT04006691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04006691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Multicenter Extension Trial Evaluating the Efficacy and Safety of UGN-101 (Mitomycin Gel) for Instillation on Ablation of Upper Urinary Tract Urothelial Carcinoma in Recurrent Patients From Trial TC-UT-03
Lead sponsor
UroGen Pharma Ltd.
Phase
Phase 3
Overall status
Withdrawn
Start date
October 1, 2019
Completion date
March 31, 2020
Enrollment
0 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, transitional cell cancer of the renal pelvis and ureter, transitional cell carcinoma